前收市價 | 284.88 |
開市 | 285.77 |
買盤 | 286.52 x 1100 |
賣出價 | 288.25 x 1300 |
今日波幅 | 285.77 - 288.75 |
52 週波幅 | 57.21 - 322.67 |
成交量 | |
平均成交量 | 388,212 |
市值 | 5.269B |
Beta 值 (5 年,每月) | -0.61 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -18.32 |
業績公佈日 | 2023年8月02日 - 2023年8月07日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 331.17 |
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. JMP has raised the price target from $182 to $312 and reiterates its Market Outperform rating. Resmetirom looks approvable based on Phase 3 MAESTRO-NASH data, the analyst said. The analyst raised POS for resmetirom to 90% in both the U.S. and EU (from 70% and 60%, respectively) with peak sales of ~$5 billion and ~$1.5 billion (compared to $3 billion
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. In the 52-week serial liver biopsy study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo. NASH resolution was observed in 26% and 30% in 80 mg and 100 mg doses, respectively, vs. 10% in the placebo. Related: Analysts
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. Consistent with the previous top-line data, the most frequently reported adverse event